Real-World Evaluation of Guselkumab for Moderate-to-Severe Ulcerative Colitis Safety and Effectiveness
Led by Second Affiliated Hospital of Wenzhou Medical University · Updated on 2026-10-20
97
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the clinical efficacy and safety of guselkumab in treating patients with moderate-to-severe ulcerative colitis. This real-world prospective cohort study examines multiple outcomes, including clinical, biochemical, and endoscopic remission, as well as histologic healing and intestinal ultrasound changes.
Participants receive an initial intravenous guselkumab induction therapy of 200 mg at weeks 0, 4, and 8. At week 12, based on clinical assessments, patients either continue with 100 mg subcutaneous injections every 8 weeks or increase to 200 mg every 4 weeks as maintenance. At week 24, patients achieving endoscopic remission switch to 100 mg every 8 weeks, while others continue the 200 mg every 4 weeks regimen.
Throughout the study, participants undergo evaluations including symptom scoring, endoscopic and biochemical assessments, and intestinal ultrasound. Key outcomes measured are endoscopic and histologic remission at 48 weeks, clinical and biochemical remission at 12 weeks, and drug persistence rates. Safety and hospitalization rates are also monitored, with the study lasting up to 48 weeks of follow-up.
CONDITIONS
Brief Title
Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis
Research Team
Y
Yi Jiang, Doctor of Medicine
G
guolong Ma, Master of Medicine
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Second Affiliated Hospital of Wenzhou Medical University
Lead Sponsor
Xian-Janssen Pharmaceutical Ltd.
Collaborating Sponsor
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Age 18 years or older
Diagnosis of ulcerative colitis confirmed by clinical symptoms, lab tests, colonoscopy, imaging, and pathology
Moderate-to-severe disease with modified Mayo score ≥ 5, rectal bleeding score ≥ 1, and Mayo endoscopic score ≥ 2
Inadequate response or intolerance to at least one conventional therapy such as 5-aminosalicylates, corticosteroids, or immunosuppressants
Patients may be biologic-naive or have failed first-line or multiple therapies
Availability of baseline data including symptom scores, endoscopy, biochemical markers, or imaging
Voluntary written informed consent provided
You will not qualify if you...
Presence of other intestinal diseases like Crohn's disease, intestinal tuberculosis, infectious or ischemic colitis
Active intestinal infection with positive pathogen tests within 8 weeks prior to study unless later cleared
Severe infections, cancers, severe liver/kidney dysfunction, or active autoimmune diseases interfering with assessment
Previous total colorectal resection or stoma surgery with unassessable disease activity or planned major intestinal surgery during study
History of severe allergic reaction to monoclonal antibodies
Pregnancy or breastfeeding
Insufficient baseline or follow-up data to assess efficacy or safety
Concurrent participation in other interventional clinical trials that may affect results
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 48 weeks
Participants receive guselkumab with intravenous doses at weeks 0, 4, and 8, followed by subcutaneous maintenance dosing based on their clinical response at weeks 12 and 24.
Regular clinical assessments at weeks 12, 24, and 48
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Phase 1 Study to Assess Safety, Tolerability, and Pharmacokinetics of BDHK-2009 Tablets in Healthy Adults Aged 18 to 55
Study of Daily Pomegranate Juice Effects on Gut Inflammation, Quality of Life, and Gut Microbiome in Adults with Mild-to-Moderate Ulcerative Colitis
Study of Etrasimod Oral Treatment in Patients 65 and Older With Active Ulcerative Colitis
Real-World Evaluation of Guselkumab for Moderate-to-Severe Ulcerative Colitis Safety and Effectiveness
Using Intestinal Ultrasound to Predict How Well Guselkumab Works in Adults With Moderate to Severe Crohns Disease
Effects of Mediterranean Diet Alone or with Time-Restricted Feeding on Gut Health and Quality of Life in Adults with Ulcerative Colitis in Remission
Effects of Partial Enteral Nutrition With LH VIOLA on Weight Loss and Muscle Loss in Adults With Inflammatory Bowel Disease at Nutritional Risk
Evaluating Safety and Effectiveness of ButyMixx Supplement for Adults with Ulcerative Colitis in Remission
Investigation of Intestinal Tissue Repair Mechanisms Using Organoid Technology in Inflammatory Bowel Disease Patients and Controls
Comparing Vedolizumab, Ustekinumab, and JAK Inhibitors for Ulcerative Colitis After Anti-TNF Alpha Therapy
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
David T Rubin, Jessica R Allegretti, Julián Panés...
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.
Christina Kapizioni, Rofaida Desoki, Danielle Lam...
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths...